Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval
Pfizer and Gilead Seen As Suitors
John Thero insists company is focused on approval and launch, as interest in European rights grow.
You may also be interested in...
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.
The addressable patient population in the US could increase by 4.5 million if new trial is successful.